Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026
Fenofibrate as adjuvant therapy in persons with active epilepsy: A double-blind, randomized, placebo-controlled trial.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess efficacy and safety of fenofibrate as adjuvant therapy on seizure control and epileptogenic biomarkers in persons with active epilepsy(a-PWE). This single-center randomized, double-blind, placebo-controlled, parallel-group trial was conducted over 6 months. a-PWE (n = 80, 40 in each group) who have ≥ 2 seizures in preceding 3 months despite receiving ≥ 2 antiseizure medications (ASMs) were randomly assigned to receive fenofibrate (145 mg orally once daily) or matching placebo adjuvant to ongoing ASMs with 3 and 6-month follow-ups. Primary outcome: percentage change in monthly seizure frequency from baseline to 6-months. Secondary outcomes: 50% responder rate, epileptogenic biomarkers (total antioxidant capacity, neurotrophin-3, high mobility group box-1), quality of life, and safety parameters. The percentage change in monthly seizure frequency (primary outcome) was significantly higher in fenofibrate {median [Inter quartile range] 57.50(4.30 to 75)} compared to the placebo [-40.20(-60.92 to 39.60)]; [median estimate with 95% confidence interval: 70 (34.60 to 102.50), (p < 0.001)] as per intention-to-treat analysis. Similarly, 50% responder rate was significantly higher in the fenofibrate group compared to placebo (60% vs. 22.5%, p = 0.001). Epileptogenic biomarkers showed no any significant difference across groups except for TAC, which increased significantly in fenofibrate compared to placebo (p = 0.01). Fenofibrate was well tolerated without any serious adverse events. Fenofibrate added to ASMs improved seizure control and TAC in a-PWE compared to placebo, suggesting potential therapeutic role in epilepsy. Clinical trials registry India: CTRI/2021/03/032317, date March 25, 2021.
Indexed as
Identifiers
42012662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.